Loay Salman, MD
Nephrology · Miami, FLNPI 1477525897
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,767 of the $13,803 with a category attached, or 99.7%. Phraxis, Inc. accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $4,267 and has fallen 99.2% since, to $36 in 2023. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5 payments — averaging $2760.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phraxis, Inc.$14K
- GSK$36
Across 8 payments — averaging $5941.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$38K
- Travere Therapeutics, Inc.$10K
What the payments were for
- Consulting fees$13,767100%
- Food & beverage$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phraxis, Inc. | 4 | $13,767 |
| GSK | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,803 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 23 | $11,111 |
| Losartan Potassium | 12 | $260 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Miami
- Gabriel ContrerasMiami$133K
- Alessia FornoniMiami$97K
- Jonathan da CostaMiami$74K
- Yelena DrexlerMiami$43K
- Jochen ReiserMiami$43K
- Alba Gonzalez-OchoaMiami$39K
- Jorge BusseMiami$28K
- David RothMiami$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.